SELDOM Pharma

MF-500 is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. MF-500 decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.

As monotherapy, is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. MF-500 is also indicated for use in combination therapy with an oral hypoglycemic agent or insulin when diet and exercise plus the single agent do not result in adequate glycemic control.

The usual starting dose of MF-500 is 500 mg once daily with the meal. Dosage increases should be made in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the meal.

Each box contains 10 blister strips of 10 tablets each

MGL-SR is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic beta-cells by facilitating Ca+2 transports across the beta-cell membranes and decreases hepatic glucose output.

Indicated for the treatment of type 2 diabetes mellitus.

The usual initial dose is 40 to 80 mg (Gliclazide) daily. The dose can be increased upto 320 mg (Gliclazide) daily in divided doses when needed. The drug should be taken before meal.

Each box contains 10 blister strips of 10 tablets each.

Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride.

Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.

In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. Initial dose and dose titration: the usual initial dose is 1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e. at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg 2 mg 3 mg 4 mg 6 mg.

Each box contains 10 blister strips of 10 tablets each

Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride.

Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.

In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. Initial dose and dose titration: the usual initial dose is 1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e. at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg 2 mg 3 mg 4 mg 6 mg.

Each box contains 10 blister strips of 10 tablets each

Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride.

Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.

In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. Initial dose and dose titration: the usual initial dose is 1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e. at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg 2 mg 3 mg 4 mg 6 mg.

Each box contains 10 blister strips of 10 tablets each

Description:

As third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.

The usual recommended dose for adults is one tablet of Glivomet twice a day before meals. Additionally, voglibose tablets may be taken before the remaining meal, as prescribed by the physician.

Each box contains 10 blister strips of 10 Tablets each

Description:

As third line treatment of Type II diabetes mellitus in adult patients when diet, exercise and the single agents and second line therapy with two drugs do not result in adequate glycemic control.

The usual recommended dose for adults is one tablet of Glivomet twice a day before meals. Additionally, voglibose tablets may be taken before the remaining meal, as prescribed by the physician.

Each box contains 10 blister strips of 10 Tablets each

Description:

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be controlled with diet and exercise alone.

5 mg/500 mg b.i.d. with meals. Increase in increments of no more than 5 mg/500 mg up to the minimum effective dose needed to adequately control blood glucose level. Maximum, 20 mg Glibenclamide and 2,000 mg metformin daily.

Each box contains 10 blister strips of 10 tablets each.

Description:

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be controlled with diet and exercise alone.

5 mg/500 mg b.i.d. with meals. Increase in increments of no more than 5 mg/500 mg up to the minimum effective dose needed to adequately control blood glucose level. Maximum, 20 mg Glibenclamide and 2,000 mg metformin daily.

Each box contains 10 blister strips of 10 tablets each.

Description:

Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.

In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. Initial dose and dose titration: the usual initial dose is 1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e. at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg 2 mg 3 mg 4 mg 6 mg.

Each box contains 10 blister strips of 10 tablets each

Description:

Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone. Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.

In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. Initial dose and dose titration: the usual initial dose is 1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e. at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg 2 mg 3 mg 4 mg 6 mg.

Each box contains 10 blister strips of 10 tablets each

Description:

• General Weakness
• Malnourishment
• Fatigue
• Convalescence
• Hospitalised patients
• Anaemia
• Immuno-compromised patients
• Hyper catabolic conditions like cancer and burns
• Fever
• Anorexia
• Acute & Chronic Infections

1 tablespoon (15g) twice daily with lukewarm milk or water.

Bottle of 200 gm.